Australia's first GLP-1 weight-loss tablets are here. How do they compare to injections?
Australia's first GLP-1 weight-loss tablets, Wegovy (Novo Nordisk) and Foundayo (Eli Lilly), have been approved and are now available. These tablets offer an alternative to existing injectable treatments, with similar effects and side effects. Wegovy costs $260-$395 monthly and is not yet subsidized. Experts emphasize the importance of a holistic approach to obesity management.
How this was made

The 30-second read
Why it matters
TGA clearance and pharmacy availability are concrete regulatory and commercialization milestones for both Wegovy and Foundayo, but the trading impact is moderated by affordability and reimbursement uncertainty.
Market read
First oral GLP-1 tablet approvals and launch in Australia for Wegovy and Foundayo, with pricing and PBS access framed as the main near-term gating factors.
What to watch
The article emphasizes PBS negotiations for Wegovy and routine requirements for tablets; without confirmed reimbursement timelines for Foundayo, near-term volume impact could be limited despite approvals.
Background
Australia previously relied on weekly injectable GLP-1s for weight management; this article frames the first oral tablet options and compares dosing, side effects, and access.
Ticker impact
Article says Novo Nordisk’s Wegovy tablet was cleared by Australia’s TGA and landed on pharmacy shelves, expanding its GLP-1 delivery format.
Shares may see supportive sentiment from the new approved tablet pathway, partially offset by uncertainty around pricing and PBS listing timing.
The piece is a first-market approval and launch in Australia, but it provides no sales guidance or uptake data, and PBS negotiations are not yet resolved.
Article reports Eli Lilly’s Foundayo weight-loss pill received TGA approval, adding a second oral GLP-1 option in Australia.
Likely mild upward bias in sentiment as the market prices in broader addressable demand for oral GLP-1, tempered by access constraints.
This is a regulatory approval and market entry story, but the article does not quantify expected volumes, pricing for Foundayo, or reimbursement status.
Market effects
Expands the competitive set for GLP-1 weight-loss in oral form, potentially shifting demand from injections to tablets and intensifying pricing and reimbursement pressure.
Australia becomes a new commercial battleground for oral GLP-1 uptake, with PBS negotiations highlighted as a key determinant of affordability.
Oral GLP-1 commercialization progress can influence global investor expectations for next-generation delivery platforms and competitive positioning.
Counterpoint
Oral tablets may not materially change total demand if side effects, dosing routines, and reimbursement limits keep adoption constrained versus injections.
Key entities
- drugWegovy
Novo Nordisk’s GLP-1 weight-loss tablet cleared by Australia’s TGA and available on pharmacy shelves.
- drugFoundayo
Eli Lilly’s GLP-1 weight-loss pill approved by Australia’s TGA.
- regulatorTherapeutic Goods Administration (TGA)
Australia’s regulator that cleared the first GLP-1 tablets for weight management.
- expert sourceMonash University (Priya Sumithran)
Comments that oral tablets have broadly similar effects to injections, with differences mainly in preference and routine.
- expert sourceUniversity of Sydney (Louise Baur)
Highlights dosing routine challenges and the need for broader access and support.




